Serving Humanity Through
Innovations in Immunology
GeoVax Labs, Inc. is a clinical-stage biotechnology company
developing human vaccines and immunotherapies against infectious
diseases and cancer using novel proprietary platforms.
Our lead program in oncology is Gedeptin® which has completed enrollment in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. Our lead infectious disease program is GEO-CM04S1, a next-generation COVID-19 vaccine, currently enrolling in two Phase 2 clinical trials, targeting high-risk, immunocompromised patient populations. In addition GEO-CM04S1 has completed enrollment of a Phase 2 clinical trial, evaluating the vaccine as a COVID-19 heterologous booster vaccine for healthy adults who initially received a mRNA vaccine.
CLINICAL-STAGE BIOTECH COMPANY
GeoVax’s development pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine (GEO-CM04S1) and therapy for advanced head and neck cancer (Gedeptin®️). Additional research and development programs include preventive vaccines against Mpox (monkeypox) and smallpox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, and Marburg), malaria and Zika virus, as well as therapies for various solid tumors.
